In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines.
HotSpot is now emerging from stealth with preclinical compounds that could become new treatments for liver disease and autoimmune disorders. As the Cambridge, MA, biotech works to bring its lead drugs into human testing, the company is also unveiling $45 million to finance its efforts.
“We’re uncovering very new biological space and then marrying that with new chemistry,” says HotSpot… Read more »
UNDERWRITERS AND PARTNERS